药用炭片联合碳酸镧治疗血液透析高磷血症的临床研究

目的探讨药用炭片联合碳酸镧治疗血液透析高磷血症的临床疗效。方法选取2014年5月—2016年5月在驻马店市中心医院治疗的血液透析高磷血症患者160例,随机分为对照组(80例)和治疗组(80例)。对照组口服碳酸镧咀嚼片,1 g/次,3次/d;治疗组在对照组基础上口服药用炭片,1.5 g/次,3次/d。两组患者均经过12周。观察比较治疗前后两组患者临床疗效和血清学指标。结果治疗后,对照组和治疗组临床总有效率分别为81.25%、93.75%,两组比较差异具有统计学意义(P0.05)。治疗后,两组血磷、血钙、血甲状旁腺激素(PTH)、超敏C反应蛋白(hs-CRP)、成纤维生长因子23(FGF-23)和钙磷乘积水平均明显降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组血清学指标低于对照组,两组比较差异具有统计学意义(P0.05)。结论药用炭片联合碳酸镧治疗血液透析高磷血症可有效改善患者生存质量,具有一定的临床推广应用价值。

Clinical study on Medicinal Charcoal Tablets combined with lanthanum carbonate in treatment of hyperphosphatemia in hemodialysis

Objective To investigate the clinical efficacy of Medicinal Charcoal Tablets combined with lanthanum carbonate in treatment of hyperphosphatemia in hemodialysis. Methods Patients (160 cases) with hyperphosphatemia in hemodialysis in Zhumadian Central Hospital from May 2014 to May 2016 were randomly divided into control (80 cases) and treatment (80 cases) groups. Patients in the control group were po administered with Lanthanum Carbonate Chewable Tablets, 1 g/time, three times daily. Patients in the treatment group were po administered with Medicinal Charcoal Tablets on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy and serological indexes were evaluated. Results After treatment, the clinical efficacy in the control and treatment groups were 81.25% and 93.75%, respectively, and there were differences between two groups (P < 0.05). After treatment, the blood phosphorus, blood calcium, PTH, hs-CRP, FGF-23, and calcium and phosphorus product levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these serological indexes in the treatment group were more obviously lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Medicinal Charcoal Tablets combined with lanthanum carbonate can effectively improve the quality of life in treatment of hyperphosphatemia, which has a certain clinical application value.